$SNPS

Glaser Shelagh sold $1.5M of SNPS (indirect holdings)

Glaser Shelagh (CFO) sold 3,394 indirectly-held shares of SYNOPSYS INC (SNPS) at $450.02 ($1.53M total) on 2026-06-12 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Glaser Shelagh
Published Jun 15, 2026, 6:03 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 15, 2026, 6:05 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$SNPS
Neutral
high confidence
Mentioned
$SNPS
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SNPSNeutralLow
01

Why it matters

A senior officer’s open-market sale is disclosed with transaction size, price, and post-transaction holdings; no new operating or market-moving information is provided.

02

Market read

Primarily a sentiment/positioning datapoint; likely limited incremental impact versus broader company fundamentals.

03

What to watch

Traders may over-weight insider sales; without changes in guidance, contracts, or regulatory developments, the signal is usually weak.

Relevance 5/10Novelty 6/10Timing: Filed 2026-06-15; transaction dated 2026-06-12.

Background

The article is an SEC EDGAR Form 4 insider transaction disclosure for Synopsys.

Company-level read

Ticker impact

$SNPSNeutralHigh confidence
Context

Synopsys CFO Glaser Shelagh filed an SEC Form 4 selling 3,394 shares in an open-market transaction under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move; any reaction is likely muted and short-lived.

Evidence & confidence

The filing is a Form 4 insider transaction with a pre-arranged 10b5-1 plan and no accompanying fundamental catalyst (no guidance, deal, or regulatory action).

Market effects

Minimal; insider selling at a single software name rarely changes sector fundamentals.

Minimal; no cross-asset or macro linkage stated.

Minimal; transaction is company-specific and not tied to global events.

Counterpoint

Because the sale is under a pre-arranged 10b5-1 plan, it may reflect liquidity/compensation mechanics rather than bearish expectations.

Key entities

  • Synopsys

    Company whose CFO filed the Form 4 insider sale disclosure.

  • Glaser Shelagh

    CFO reporting an open-market sale of SNPS shares under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$SNPSMed

SNPS Upgraded by Morgan Stanley -- Price Target Maintained at $5

Morgan Stanley upgraded Synopsys (SNPS) to Overweight, maintaining a $500 price target. The stock is trading at $396.11, which is 39.9% undervalued according to its GF Value™ of $659.20. Synopsys has a GF Score™ of 88/100, indicating strong growth potential but concerns about valuation. Insider activity shows significant selling, with $40.7 million in sales over the last three months.

$SNPSMedAI 9/10

How to Play SNPS Stock as Layoffs Hit Synopsys

Synopsys (SNPS) reported Q3 FY2026 earnings with revenue of $2.48B, up 42.4% YoY, and EPS of $3.91, beating estimates. The company raised its full-year outlook. Analysts maintain 'Buy' ratings with price targets up to $633, citing long-term growth potential in semiconductor design.

$SNPSMedAI 8/10

Synopsys Falls as Strong Results Fail to Clear a High Bar

Synopsys (SNPS) shares fell 5.9% after reporting Q3 revenue of $2.48B and EPS of $3.91, both above guidance. The company raised full-year targets to $9.715B revenue and $15.07 EPS, but investors reacted negatively due to modest outlook increases, restructuring costs, and acquisition-related expenses. Insider sales and mixed hedge fund activity were also noted.